Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06146075
Other study ID # 65794646
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date December 2024
Est. completion date December 2026

Study information

Verified date November 2023
Source Power Life Sciences Inc.
Contact Michael B Gill
Phone 4159004227
Email bask@withpower.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Clinical trials centered on anorexia serve a pivotal function in assessing the safety and effectiveness of emerging treatments for this condition. The primary aim revolves around meticulously scrutinizing both trial completion rates and instances of voluntary withdrawal within specific patient cohort.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 500
Est. completion date December 2026
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Aged = 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed - Diagnosis of anorexia - No prior treatment for anorexia Exclusion Criteria: - Pregnant or lactating women - Any serious and/or unstable pre-existing medical disorders - Patients receiving any other investigational agents

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Power Life Sciences San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
Power Life Sciences Inc.

Country where clinical trial is conducted

United States, 

References & Publications (3)

Matsuo N, Morita T, Matsuda Y, Okamoto K, Matsumoto Y, Kaneishi K, Odagiri T, Sakurai H, Katayama H, Mori I, Yamada H, Watanabe H, Yokoyama T, Yamaguchi T, Nishi T, Shirado A, Hiramoto S, Watanabe T, Kohara H, Shimoyama S, Aruga E, Baba M, Sumita K, Iwase S. Predictors of responses to corticosteroids for anorexia in advanced cancer patients: a multicenter prospective observational study. Support Care Cancer. 2017 Jan;25(1):41-50. doi: 10.1007/s00520-016-3383-z. Epub 2016 Aug 18. — View Citation

Peters K, Meule A, Voderholzer U, Rauh E. Effects of interval-based inpatient treatment for anorexia nervosa: An observational study. Brain Behav. 2021 Nov;11(11):e2362. doi: 10.1002/brb3.2362. Epub 2021 Sep 20. — View Citation

Tanahashi T, Kawai K, Tatsushima K, Saeki C, Wakabayashi K, Tamura N, Ando T, Ishikawa T. Purging behaviors relate to impaired subjective sleep quality in female patients with anorexia nervosa: a prospective observational study. Biopsychosoc Med. 2017 Aug 16;11:22. doi: 10.1186/s13030-017-0107-7. eCollection 2017. Erratum In: Biopsychosoc Med. 2018 Mar 15;12 :5. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients who decide to enroll in an anorexia clinical research 3 months
Primary Rate of patients who remain in an anorexia clinical trial to trial completion 12 months
See also
  Status Clinical Trial Phase
Withdrawn NCT01501396 - Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite Phase 2
Withdrawn NCT02793102 - Sensory Workshops and Anorexia Nervosa N/A
Active, not recruiting NCT01206335 - Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia Phase 2
Completed NCT02524301 - Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study N/A
Active, not recruiting NCT00488072 - Effects of Mirtazapine on Appetite in Advanced Cancer Patients Phase 2
Withdrawn NCT05039385 - Exercise Program in Patients With Anorexia Nervosa (ESATRAL) N/A
Completed NCT03097874 - Adaptive Treatment for Adolescent Anorexia Nervosa N/A
Completed NCT00031785 - Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer Phase 3
Terminated NCT00535015 - Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer Phase 2
Terminated NCT00558558 - Haelan and Nutrition in Cancer Patients Phase 2
Completed NCT00040885 - Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05) Phase 3
Completed NCT00006799 - Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Phase 3
Active, not recruiting NCT03637816 - Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer Phase 2/Phase 3
Completed NCT04007900 - Positive Affect Treatment (PAT) to Target Reward Mechanisms in Anorexia Nervosa N/A
Completed NCT00735540 - Clinical Diagnosis of Teenagers Admitted to Pediatric Departments N/A
Completed NCT00046904 - Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer Phase 3
Completed NCT04803305 - Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia Phase 1
Completed NCT05708404 - Outpatient Treatment of Severe and Enduring Anorexia Nervosa
Completed NCT03283488 - Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care. Phase 2
Recruiting NCT05503147 - Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients (CanPan) Phase 1